p16/p53 gene therapy - DeveloGen
Latest Information Update: 25 Jul 2001
At a glance
- Originator DeveloGen
- Class
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Liver cancer
Most Recent Events
- 25 Jul 2001 Discontinued-Preclinical for Liver cancer in Germany (Unknown route)
- 27 Nov 2000 HepaVec has been acquired by DeveloGen
- 07 Dec 1999 New profile